Chemoprevention of pituitary gonadotrope tumors

垂体促性腺激素肿瘤的化学预防

• 批准号: 8774884
• 负责人: T. RAJENDRA KUMAR
• 金额: $ 31.33万
• 依托单位: UNIVERSITY OF KANSAS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-01-01 至 2015-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8774884
• 关键词: Acute; Antiestrogen Therapy; Biological Markers; Biological Models; Blindness; Carcinoma; Chemoprevention; Chemopreventive Agent; Clinical; Confocal Microscopy; Data; Development; Diagnostic; Early Diagnosis; Erinaceidae; Estrogen Antagonists; Estrogen Receptor 1; Estrogen Receptors; Estrogen Therapy; Estrogens; Failure; Follicle Stimulating Hormone; Frequencies; Gene Expression Profiling; General Population; Glycoproteins; Goals; Green Fluorescent Proteins; Growth; Headache; Health; Hemorrhage; Hormones; Human; Hypopituitarism; In Vitro; Intracranial Hypertension; Intracranial Neoplasms; Itraconazole; Knowledge; Label; Lasers; Luteinizing Hormone; Messenger RNA; MicroRNAs; Mission; Mitogen-Activated Protein Kinases; Molecular Profiling; Mouse Strains; Mus; Nausea; Neurologic; Null Lymphocytes; Operative Surgical Procedures; Optic Chiasm; Pathogenesis; Pathway interactions; Patients; Phenocopy; Phosphorylation; Pituitary Diseases; Pituitary Gland; Pituitary Gland Adenoma; Pituitary Neoplasms; Prevalence; Prevention; Preventive; Production; Public Health; Receptor Signaling; Recurrence; Research; Signal Transduction; Sorting - Cell Movement; Staging; Symptoms; Tamoxifen; Testing; Time; Transgenic Mice; Transgenic Organisms; adenoma; base; brain tissue; clinically relevant; cyclopamine; cytokine; disability; efficacy testing; glycosylation; in vivo; in vivo Model; inhibitor/antagonist; innovation; insight; mouse model; novel; overexpression; sex; smoothened signaling pathway; tumor; tumor growth; tumor progression

DESCRIPTION (provided by applicant): Pituitary adenomas are the most frequent of all pituitary diseases and are observed in both sexes. The prevalence is estimated as ~90 cases per 105 people. The majority arises from the gonadotrope lineage and these tumors do not hypersecrete glycoprotein hormones [i.e., luteinizing hormone (LH) and follicle stimulating hormone (FSH)] and thus are called null cell adenomas. The clinical manifestations include neurological symptoms such as damage to brain tissue and optic chiasm, vision loss, increased intracranial pressure, persistent headache and nausea. Because they have no well-defined diagnostic markers, null cell adenomas often go undetected until they are very advanced and surgery is the only treatment. There are no established model systems or chemoprevention options available for null cell adenomas. We have developed a unique transgenic strain of mice that develops gonadotrope-enriched pituitary adenomas and phenocopies human pituitary null cell adenomas including. Our long-term goal is to understand the mechanisms of origin and progression of null cell adenoma, and develop new strategies of chemoprevention for it. The objective of this proposal is to identify biomarkers and specific targets/pathways responsible for gonadotrope tumor progression such that mechanistic insights into progression and prevention of human null cell adenomas could ultimately be obtained. Our central hypothesis is that both estrogen receptor-1 (ESR1) and Indian hedgehog (IHH) contribute to growth of pituitary gonadotrope adenomas and inhibiting their expression leads to clinical benefit. In Specific Aim 1, we will determine the mechanism by which estrogen signaling influences tumor growth and progression. Effects of estrogen on glycosylation that contribute to hormone secretion failure will be evaluated. Additionally, a novel mouse model in which gonadotrope tumors are fluorescently labeled will be used to identify potential biomarkers. In Specific Aim 2, we will test the efficacyof anti-estrogen therapy to regulate gonadotrope tumor growth. The approach involves the use of mice conditionally overexpressing Esr1 at desired times, and mice lacking either Esr1 or Esr2 on the tumor-prone transgenic background. The in vivo tumor preventive effects of tamoxifen will also be tested. In Specific Aim 3, we will determine the effects of blocking IHH action on gonadotrope tumor development. We will specifically delete Ihh in gonadotrope tumors by using a cre-lox approach. In a second approach, the effects of hedgehog chemoprevention agents will be tested in gonadotrope tumors of transgenic mice. The approach is innovative, because it utilizes a unique transgenic mouse model that develops gonadotrope tumors and uses a combination of in vitro and novel in vivo models. The proposed research is significant because it is expected to vertically advance and expand understanding of how chemopreventive agents targeted to block estrogen and hedgehog signaling regulate gonadotrope/null cell adenomas.

描述(申请人提供)：垂体腺瘤是所有垂体疾病中最常见的一种，男女均可观察到。流行率估计为每105人约90例。大多数起源于促性腺激素谱系，这些肿瘤不会过度分泌糖蛋白激素[即黄体生成素(LH)和卵泡刺激素(FSH)]，因此被称为空细胞腺瘤。临床表现包括脑组织损伤和视交叉、视力丧失、颅内压升高、持续性头痛和恶心等神经系统症状。由于没有明确的诊断标记物，空细胞腺瘤通常不会被发现，直到病情非常严重，手术是唯一的治疗方法。对于空细胞腺瘤，尚无已建立的模型系统或化学预防方案可用。我们已经开发出一种独特的转基因小鼠品系，它可以产生富含促性腺激素的垂体腺瘤和人类垂体零细胞腺瘤，包括。我们的长期目标是了解空细胞腺瘤的发生和发展机制，并为其开发新的化学预防策略。这项建议的目的是确定与促性腺激素肿瘤进展有关的生物标志物和特定靶点/途径，以便最终能够从机制上深入了解人类空细胞腺瘤的进展和预防。我们的中心假设是雌激素受体-1(ESR1)和印度刺猬(IHH)都有助于垂体促性腺激素腺瘤的生长，抑制它们的表达可以带来临床益处。在特定的目标1中，我们将确定雌激素信号影响肿瘤生长和进展的机制。雌激素对导致激素分泌失败的糖基化的影响 被评估。此外，一种新的小鼠模型，其中促性腺激素肿瘤被荧光标记，将被用于识别潜在的生物标记物。在特定的目标2中，我们将测试抗雌激素治疗对促性腺激素肿瘤生长的调节作用。该方法包括使用在所需时间有条件地过表达ESR1的小鼠，以及在易患肿瘤的转基因背景下缺乏ESR1或ESR2的小鼠。他莫昔芬的体内肿瘤预防作用也将得到测试。在具体目标3中，我们将确定阻断IHH作用对促性腺激素肿瘤发展的影响。我们将使用cre-lox方法专门删除促性腺激素肿瘤中的IHH。在第二种方法中，将在转基因小鼠的促性腺激素肿瘤中测试刺猬化学预防药物的效果。这种方法是创新的，因为它利用了一种独特的转基因小鼠模型，这种模型会发展成促性腺激素肿瘤，并使用了体外模型和新的体内模型的组合。这项拟议的研究具有重要意义，因为它有望纵向推进和扩大对以阻断雌激素和刺猬信号为靶点的化学预防药物如何调节促性腺激素/零细胞腺瘤的理解。